论文部分内容阅读
目的探讨长期吸入丙酸氟替卡松对哮喘儿童骨代谢的影响。方法 41例支气管哮喘患儿随机分成两组,观察组20例吸入丙酸氟替卡松(FP),对照组21例吸入二丙酸倍氯米松(BDP),疗程均为1年。观察两组吸药前后骨钙素(OC)、碱性磷酸酶(ALP)、Ⅰ型胶原羧基端伸展肽(ICTP)、Ⅰ型胶原氨基端肽(PICP)及血Ca2+,P3-含量,并与20例健康组比较;观察两组身高、体重增长速率。结果治疗前观察组、对照组、健康组3组骨代谢指标含量比较差异均无统计学意义(P均>0.05);治疗后观察组、对照组骨代谢指标含量比较差异无统计学意义(P>0.05);治疗1年后两组身高生长速率、体重增长速率比较差异均无统计学意义(P均>0.05)。结论长期吸入丙酸氟替卡松防治儿童哮喘安全、有效,不影响患儿骨代谢、身高和体重增长速率。
Objective To investigate the effect of long-term inhalation of fluticasone propionate on bone metabolism in asthmatic children. Methods Forty-one children with bronchial asthma were randomly divided into two groups. In the observation group, 20 patients received inhalation of fluticasone propionate (FP), while 21 patients in the control group received inhaled beclomethasone dipropionate (BDP) for 1 year. The levels of osteocalcin (OC), alkaline phosphatase (ALP), type Ⅰ collagen carboxyl terminal extensile peptide (ICTP), collagen type Ⅰ collagen peptide (PICP) and blood Ca2 +, P3- Compared with 20 healthy subjects, the height and weight growth rate of the two groups were observed. Results There was no significant difference in the bone metabolic parameters between the observation group, control group and healthy group before treatment (P> 0.05). There was no significant difference in the bone metabolic parameters between the observation group and the control group after treatment (P > 0.05). There was no significant difference in height growth rate and weight growth rate between the two groups after 1 year of treatment (all P> 0.05). Conclusion Long-term inhalation of fluticasone propionate in children with asthma is safe and effective, and does not affect the rate of bone metabolism, height and weight gain in children.